Detailed Information on Publication Record
2018
Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?
KAZDA, Tomáš, Adam DZIACKY, Petr BURKOŇ, Petr POSPÍŠIL, Marek SLÁVIK et. al.Basic information
Original name
Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?
Authors
KAZDA, Tomáš (203 Czech Republic, belonging to the institution), Adam DZIACKY (703 Slovakia, belonging to the institution), Petr BURKOŇ (203 Czech Republic, belonging to the institution), Petr POSPÍŠIL (203 Czech Republic, belonging to the institution), Marek SLÁVIK (703 Slovakia, belonging to the institution), Zdeněk ŘEHÁK (203 Czech Republic, belonging to the institution), Radim JANČÁLEK (203 Czech Republic, belonging to the institution), Pavel ŠLAMPA (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Radek LAKOMÝ (203 Czech Republic, guarantor, belonging to the institution)
Edition
RADIOLOGY AND ONCOLOGY, LJUBLJANA, ASSOC RADIOLOGY & ONCOLOGY, 2018, 1318-2099
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30224 Radiology, nuclear medicine and medical imaging
Country of publisher
Germany
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.846
RIV identification code
RIV/00216224:14110/18:00104694
Organization unit
Faculty of Medicine
UT WoS
000433103400001
Keywords in English
glioblastoma; radiation therapy; controversy; target volumes; radiotherapy dosage
Tags
International impact, Reviewed
Změněno: 12/3/2019 16:02, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Background. The current standard of care of glioblastoma, the most common primary brain tumor in adults, has remained unchanged for over a decade. Nevertheless, some improvements in patient outcomes have occurred as a consequence of modern surgery, improved radiotherapy and up-to-date management of toxicity. Patients from control arms (receiving standard concurrent chemoradiotherapy and adjuvant chemotherapy with temozolomide) of recent clinical trials achieve better outcomes compared to the median survival of 14.6 months reported in Stupp's landmark clinical trial in 2005. The approach to radiotherapy that emerged from Stupp's trial, which continues to be a basis for the current standard of care, is no longer applicable and there is a need to develop updated guidelines for radiotherapy within the daily clinical practice that address or at least acknowledge existing controversies in the planning of radiotherapy. The goal of this review is to provoke critical thinking about potentially controversial aspects in the radiotherapy of glioblastoma, including among others the issue of target definitions, simultaneously integrated boost technique, and hippocampal sparing. Conclusions. In conjunction with new treatment approaches such as tumor-treating fields (TTF) and immunotherapy, the role of adjuvant radiotherapy will be further defined. The personalized approach in daily radiotherapy practice is enabled with modern radiotherapy systems.
Links
| LQ1601, research and development project |
|